Inventiva (NASDAQ:IVA) Research Coverage Started at TD Cowen

TD Cowen initiated coverage on shares of Inventiva (NASDAQ:IVA) in a research note published on Friday morning, MarketBeat.com reports. The brokerage issued a buy rating and a $10.00 price objective on the stock.

IVA has been the topic of a number of other research reports. HC Wainwright restated a “buy” rating and issued a $13.00 target price on shares of Inventiva in a research note on Thursday, January 30th. Stifel Nicolaus lowered their price objective on Inventiva from $20.00 to $17.00 and set a “buy” rating on the stock in a research report on Friday, November 22nd. Finally, UBS Group initiated coverage on shares of Inventiva in a report on Tuesday, November 12th. They set a “neutral” rating and a $3.00 target price for the company. One investment analyst has rated the stock with a hold rating and four have given a buy rating to the company. According to MarketBeat.com, Inventiva presently has a consensus rating of “Moderate Buy” and an average price target of $12.60.

Inventiva Stock Performance

NASDAQ IVA opened at $2.84 on Friday. Inventiva has a 1 year low of $1.53 and a 1 year high of $4.50. The company has a fifty day moving average of $2.33 and a 200 day moving average of $2.36.

About Inventiva

Inventiva SA, a clinical-stage biopharmaceutical company, focuses on the development of oral small molecule therapies for the treatment of non-alcoholic steatohepatitis (NASH) and other diseases. Its lead product candidate is Lanifibranor, which is in Phase III clinical trial to treat NASH. The company also develops Odiparcil for the treatment of patients with mucopolysaccharidoses type VI.